Molecules secreted by the osteoclast or ‘clastokynes’ are essential to stimulate bone formation by osteoblasts. Treatments with bisphosphates and Denosumab target osteoclast survival and differentiation. This suppresses bone turnover and is suspected to increase the risk of atypical fractures in the long term. A solution to overcome this is to develop strategies that target selectively the activity of osteoclasts without affecting their survival or differentiation. S...
This site uses cookies
Essential cookies
Some cookies are essential and the website may not work correctly without them. These cookies can only be removed by changing your browser preferences.
Other cookies
We use tracking cookies and other non-essential cookies to help improve our services.
We place cookies on your device to give you the best experience of this website. If you don't change your cookie settings, we'll assume you're happy with this.